Serotonin and the heart

WH Frishman, P Grewall - Annals of medicine, 2000 - Taylor & Francis
Serotonin is a naturally occurring vasoactive substance that has diverse cardio-
physiological effects. These effects can be explained by the existence of serotonin receptor …

Serotonin and serotonin antagonism in cardiovascular and non‐cardiovascular disease

WH Frishman, S Huberfeld, S Okin… - The Journal of …, 1995 - Wiley Online Library
Serotonin, or 5‐hydroxytryptamine, is a naturally‐occurring vasoactive substance found
primarily in the brain, enterochromaffin tissue, and blood platelets. It has diffuse …

Ketanserin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease

RN Brogden, EM Sorkin - Drugs, 1990 - Springer
Ketanserin is a 5-HT 2 receptor antagonist without partial agonist properties which also
possesses weak α 1-adrenoceptor antagonistic activity, which may explain its …

Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension

T Hedner, B Persson - American Journal of Hypertension, 1988 - academic.oup.com
Ketanserin is an agent whose main pharmacologic action is antagonism of serotonin (5-
hydroxytryptamine, 5HT) receptors of the 5HT2 subtype. It also has weak α1-adrenergic …

Serotonin antagonism and serotonin antagonists in pregnancy: role of ketanserin

DW Steyn, HJ Odendaal - Obstetrical & gynecological survey, 2000 - journals.lww.com
Most agree that antihypertensive medication should be used to treat severe hypertension
during pregnancy, but its role in patients with mild to moderate disease is debated. None of …

Kinetics of serotonin in platelets in essential hypertension

S Nityanand, BL Tekwani, M Chandra, K Shanker… - Life sciences, 1990 - Elsevier
In a study of the kinetics of 5-hydroxytryptamine (5-HT) in platelets in 26 hypertensive
subjects with a mean systolic and diastolic blood pressure of 153.9±26.9 and 106.9±9.1 mm …

QT prolongation and torsade de pointes ventricular tachycardia produced by Ketanserin

AE Aldariz, H Romero, M Baroni… - Pacing and Clinical …, 1986 - Wiley Online Library
A 65‐year‐old man with arterial hypertension received oral treatment with Ketanserin, a new
drug, during a period of five months. He developed marked QT interval prolongation and …

Pharmacokinetic-pharmacodynamic relationships of α-adrenoceptor antagonists

R Donnelly, PA Meredith, HL Elliott - Clinical pharmacokinetics, 1989 - Springer
Competitive α 1-adrenoceptor antagonists are effective in the treatment of both hypertension
and cardiac failure. Prazosin has both a short half-life and a short duration of action, but …

Pharmacokinetics of ketanserin in patients with essential hypertension

B Persson, A Pettersson, T Hedner - European journal of clinical …, 1987 - Springer
The pharmacokinetics of ketanserin and its main metabolite ketanserin-ol, and the
antihypertensive effects of intravenous, single oral and chronic oral (40 mg once daily) …

Ketanserin: a novel cardiovascular drug

J Symoens, M Janssens - Drug Development Research, 1986 - Wiley Online Library
Extensive clinical investigation has shown that ketanserin is an effective first‐line
antihypertensive agent with particular advantages in older patients. It has a favorable …